RU2016102083A - Соединения, направленные на Gadd45β, и их включающая фармацевтическая композиция - Google Patents
Соединения, направленные на Gadd45β, и их включающая фармацевтическая композиция Download PDFInfo
- Publication number
- RU2016102083A RU2016102083A RU2016102083A RU2016102083A RU2016102083A RU 2016102083 A RU2016102083 A RU 2016102083A RU 2016102083 A RU2016102083 A RU 2016102083A RU 2016102083 A RU2016102083 A RU 2016102083A RU 2016102083 A RU2016102083 A RU 2016102083A
- Authority
- RU
- Russia
- Prior art keywords
- tyr
- phe
- arg
- acetyl
- benzyloxycarbonyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 10
- 239000008194 pharmaceutical composition Substances 0.000 title claims 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 10
- -1 2-chloro-benzyloxycarbonyl Chemical group 0.000 claims 5
- 229930182827 D-tryptophan Natural products 0.000 claims 5
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims 5
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 claims 4
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims 3
- 229930195709 D-tyrosine Natural products 0.000 claims 3
- 150000003862 amino acid derivatives Chemical class 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- KKLJGAZXRLWHMB-UFYCRDLUSA-N (2s)-1-[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]-n-[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C1=CC=C(O)C=C1 KKLJGAZXRLWHMB-UFYCRDLUSA-N 0.000 claims 2
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 claims 2
- 229930182832 D-phenylalanine Natural products 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- JUQLUIFNNFIIKC-RXMQYKEDSA-N (2r)-2-aminoheptanedioic acid Chemical compound OC(=O)[C@H](N)CCCCC(O)=O JUQLUIFNNFIIKC-RXMQYKEDSA-N 0.000 claims 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims 1
- AHLPHDHHMVZTML-SCSAIBSYSA-N D-Ornithine Chemical compound NCCC[C@@H](N)C(O)=O AHLPHDHHMVZTML-SCSAIBSYSA-N 0.000 claims 1
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 claims 1
- 229930028154 D-arginine Natural products 0.000 claims 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 claims 1
- 229930182847 D-glutamic acid Natural products 0.000 claims 1
- ZDXPYRJPNDTMRX-GSVOUGTGSA-N D-glutamine Chemical compound OC(=O)[C@H](N)CCC(N)=O ZDXPYRJPNDTMRX-GSVOUGTGSA-N 0.000 claims 1
- 229930195715 D-glutamine Natural products 0.000 claims 1
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 claims 1
- 229930195721 D-histidine Natural products 0.000 claims 1
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 claims 1
- 229930182819 D-leucine Natural products 0.000 claims 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims 1
- FFEARJCKVFRZRR-SCSAIBSYSA-N D-methionine Chemical compound CSCC[C@@H](N)C(O)=O FFEARJCKVFRZRR-SCSAIBSYSA-N 0.000 claims 1
- 229930182818 D-methionine Natural products 0.000 claims 1
- 229930182820 D-proline Natural products 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 229960002684 aminocaproic acid Drugs 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000004494 ethyl ester group Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
- C07K5/06113—Asp- or Asn-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0918579.4 | 2009-10-22 | ||
| GBGB0918579.4A GB0918579D0 (en) | 2009-10-22 | 2009-10-22 | Gadd45beta targeting agents |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012120905/04A Division RU2577311C2 (ru) | 2009-10-22 | 2010-10-22 | СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАКОВОГО ЗАБОЛЕВАНИЯ У ЧЕЛОВЕКА, КОТОРОЕ ХАРАКТЕРИЗУЕТСЯ ПОВЫШЕННЫМ УРОВНЕМ ЭКСПРЕССИИ ИЛИ АКТИВНОСТИ Gadd45β ПО СРАВНЕНИЮ С ОБЫЧНЫМИ ЗДОРОВЫМИ КЛЕТКАМИ, В СЛУЧАЕ ЗАВИСИМОСТИ ЖИЗНЕСПОСОБНОСТИ И/ИЛИ РОСТА РАКОВЫХ КЛЕТОК ОТ NF-кВ, И ТРИПЕПТИД. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2016102083A true RU2016102083A (ru) | 2018-11-20 |
Family
ID=41426579
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016102083A RU2016102083A (ru) | 2009-10-22 | 2010-10-22 | Соединения, направленные на Gadd45β, и их включающая фармацевтическая композиция |
| RU2012120905/04A RU2577311C2 (ru) | 2009-10-22 | 2010-10-22 | СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАКОВОГО ЗАБОЛЕВАНИЯ У ЧЕЛОВЕКА, КОТОРОЕ ХАРАКТЕРИЗУЕТСЯ ПОВЫШЕННЫМ УРОВНЕМ ЭКСПРЕССИИ ИЛИ АКТИВНОСТИ Gadd45β ПО СРАВНЕНИЮ С ОБЫЧНЫМИ ЗДОРОВЫМИ КЛЕТКАМИ, В СЛУЧАЕ ЗАВИСИМОСТИ ЖИЗНЕСПОСОБНОСТИ И/ИЛИ РОСТА РАКОВЫХ КЛЕТОК ОТ NF-кВ, И ТРИПЕПТИД. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012120905/04A RU2577311C2 (ru) | 2009-10-22 | 2010-10-22 | СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАКОВОГО ЗАБОЛЕВАНИЯ У ЧЕЛОВЕКА, КОТОРОЕ ХАРАКТЕРИЗУЕТСЯ ПОВЫШЕННЫМ УРОВНЕМ ЭКСПРЕССИИ ИЛИ АКТИВНОСТИ Gadd45β ПО СРАВНЕНИЮ С ОБЫЧНЫМИ ЗДОРОВЫМИ КЛЕТКАМИ, В СЛУЧАЕ ЗАВИСИМОСТИ ЖИЗНЕСПОСОБНОСТИ И/ИЛИ РОСТА РАКОВЫХ КЛЕТОК ОТ NF-кВ, И ТРИПЕПТИД. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8993717B2 (OSRAM) |
| EP (2) | EP3178836B1 (OSRAM) |
| JP (2) | JP5961113B2 (OSRAM) |
| KR (1) | KR20120099440A (OSRAM) |
| CN (1) | CN102741269B (OSRAM) |
| AU (1) | AU2010309594B2 (OSRAM) |
| BR (1) | BR112012011332B1 (OSRAM) |
| CA (2) | CA3034860A1 (OSRAM) |
| GB (1) | GB0918579D0 (OSRAM) |
| IL (1) | IL219325B (OSRAM) |
| IN (1) | IN2012DN03310A (OSRAM) |
| MX (1) | MX357801B (OSRAM) |
| RU (2) | RU2016102083A (OSRAM) |
| WO (1) | WO2011048390A2 (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0918579D0 (en) | 2009-10-22 | 2009-12-09 | Imp Innovations Ltd | Gadd45beta targeting agents |
| PL219569B1 (pl) | 2010-02-19 | 2015-05-29 | Peptaderm Spółka Z Ograniczoną Odpowiedzialnością | Cykliczne tetrapeptydy i ich zastosowanie |
| GB201107118D0 (en) * | 2011-04-27 | 2011-06-08 | Imp Innovations Ltd | Method of diagnosis and prognosis |
| WO2013055051A1 (ko) * | 2011-10-14 | 2013-04-18 | 서울대학교산학협력단 | 펩타이드 나노구조체 및 그 제조 방법 |
| EP3777876B1 (en) | 2011-10-28 | 2023-08-09 | NeoStrata Company, Inc. | N-acyldipeptide derivatives and their uses |
| WO2013142376A1 (en) * | 2012-03-19 | 2013-09-26 | Aposignal Bioscience Llc | Composition and methods for cell modulation |
| CN104817618B (zh) * | 2014-01-30 | 2018-07-03 | 陈光健 | 寡肽cd01及其制备方法和应用 |
| CN104817616A (zh) * | 2014-01-30 | 2015-08-05 | 陈光健 | 寡肽cd02及其制备方法和应用 |
| GB201414542D0 (en) * | 2014-08-15 | 2014-10-01 | Imp Innovations Ltd | Novel therapy |
| CN111606972B (zh) * | 2019-01-30 | 2022-04-05 | 浙江省医学科学院 | 一种鳕鱼皮寡肽及其分离纯化和在制备ɑ-葡萄糖苷酶抑制剂及抗Ⅱ型糖尿病药物中的应用 |
| RU2716258C1 (ru) * | 2019-07-30 | 2020-03-11 | Автономная некоммерческая образовательная организация высшего образования Сколковский институт науки и технологий | Пептидный антагонист нмда-рецептора |
| KR102417496B1 (ko) * | 2019-11-29 | 2022-07-06 | (주)수파드엘릭사 | 안드로겐 수용체의 활성을 억제하는 폡타이드 및 이를 이용하는 화장료 조성물 |
| KR102348728B1 (ko) * | 2020-03-23 | 2022-01-12 | 주식회사 엘베이스 | 암의 예방 또는 치료용 약학적 조성물 |
| WO2021194228A1 (ko) * | 2020-03-23 | 2021-09-30 | 주식회사 엘베이스 | 암의 예방 또는 치료용 약학적 조성물 |
| PH12022553378A1 (en) | 2020-06-10 | 2024-03-25 | Univ Leuven Kath | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections |
| WO2022203219A1 (ko) * | 2021-03-22 | 2022-09-29 | 주식회사 엘베이스 | 암의 예방 또는 치료용 약학적 조성물 |
| CN115605495A (zh) * | 2021-03-22 | 2023-01-13 | L 基础有限公司（Kr） | 用于预防或治疗癌症的药物组合物 |
| EP4366831A4 (en) | 2021-07-09 | 2025-06-11 | Aligos Therapeutics, Inc. | ANTI-VIRAL COMPOUNDS |
| IT202100023357A1 (it) * | 2021-09-09 | 2023-03-09 | Cheirontech S R L | Peptidi con attività anti-angiogenica |
| US12065428B2 (en) | 2021-09-17 | 2024-08-20 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| WO2023043261A1 (ko) * | 2021-09-17 | 2023-03-23 | 주식회사 엘베이스 | 항암제의 항암 효과 증진용 약학적 조성물 |
| KR102786112B1 (ko) * | 2021-09-17 | 2025-03-27 | 주식회사 엘베이스 | 항암제의 항암 효과 증진용 약학적 조성물 |
| WO2023043269A1 (ko) * | 2021-09-17 | 2023-03-23 | 주식회사 엘베이스 | 면역반응을 조절하기 위한 약학적 조성물 |
| KR102494749B1 (ko) * | 2021-09-17 | 2023-02-06 | 주식회사 엘베이스 | 암 치료용 cage 저해제에 대한 반응자 특성화 방법 |
| CN116350746B (zh) * | 2023-05-16 | 2024-03-22 | 海口桥水联合科技有限责任公司 | 沙丁鱼肽组合物在治疗过敏性鼻炎的药物中的应用 |
| CN119874809A (zh) * | 2025-01-13 | 2025-04-25 | 广东工业大学 | 一类抗氧化肽及其制备方法和应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| HU187461B (en) | 1981-10-22 | 1986-01-28 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu | Process for producing n-nitrozo-n-bracket-beta-chloroethyl-bracket closed-carbamoyl-peptides of citostatic activity |
| CA1257199A (en) | 1986-05-20 | 1989-07-11 | Paul Y. Wang | Preparation containing bioactive macromolecular substance for multi-months release in vivo |
| DE3813989A1 (de) * | 1987-04-29 | 1988-11-10 | Hoechst Ag | Peptide mit phospholipase a(pfeil abwaerts)2(pfeil abwaerts)-hemmender wirkung |
| IT1243390B (it) | 1990-11-22 | 1994-06-10 | Vectorpharma Int | Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione. |
| US5907030A (en) | 1995-01-25 | 1999-05-25 | University Of Southern California | Method and compositions for lipidization of hydrophilic molecules |
| US5962270A (en) | 1996-02-06 | 1999-10-05 | Bionebraska, Inc. | Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs |
| US6737408B1 (en) * | 1997-08-07 | 2004-05-18 | University Of Cincinnati | Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm |
| US6093692A (en) | 1997-09-25 | 2000-07-25 | The University Of Southern California | Method and compositions for lipidization of hydrophilic molecules |
| FR2774674B1 (fr) | 1998-02-10 | 2000-03-24 | Atochem Elf Sa | Procede de preparation d'une solution aqueuse de peroxyde d'hydrogene directement a partir d'hydrogene et d'oxygene et dispositif permettant sa mise en oeuvre |
| US5993414A (en) | 1998-04-23 | 1999-11-30 | Medtronic, Inc. | Implantable device |
| US20030162223A1 (en) * | 1999-10-22 | 2003-08-28 | Lowery David E. | Drosophila G protein coupled receptors, nucleic acids, and methods related to the same |
| US6436091B1 (en) | 1999-11-16 | 2002-08-20 | Microsolutions, Inc. | Methods and implantable devices and systems for long term delivery of a pharmaceutical agent |
| US7723303B2 (en) * | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| EP1388537A1 (en) * | 2001-05-15 | 2004-02-11 | Taisho Pharmaceutical Co., Ltd | Arginine derivatives |
| KR100889993B1 (ko) * | 2001-07-13 | 2009-03-25 | 씨엠에스 펩티드 패턴트 홀딩 컴퍼니 리미티드 | 생물학적 활성 펩타이드 |
| US7354898B2 (en) * | 2001-10-02 | 2008-04-08 | University Of Chicago | Identification of novel factors that block programmed cell death or apoptosis by targeting JNK |
| EP1453467A4 (en) | 2001-10-02 | 2008-01-09 | Univ Chicago | METHODS AND COMPOSITIONS FOR MODULATING APOPTOSIS |
| JP2006506975A (ja) | 2002-08-19 | 2006-03-02 | イェン、ユン | 肝疾患の治療 |
| CA2522758A1 (en) * | 2003-04-22 | 2004-11-04 | Avanir Pharmaceuticals | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia |
| US7084111B2 (en) * | 2003-06-23 | 2006-08-01 | University Of Florida Research Foundation, Inc. | Melanocortin receptor templates, peptides, and use thereof |
| WO2006049597A1 (en) * | 2004-10-27 | 2006-05-11 | Avanir Pharmaceuticals | Amino acid-derived compounds as modulators of the reverse cholesterol transport |
| CN102584939B (zh) * | 2005-01-13 | 2014-08-06 | 卧龙岗大学 | 肽化合物 |
| CN101155825B (zh) | 2005-02-09 | 2014-11-26 | 赫里克斯生物医疗公司 | 抗微生物六肽 |
| US7919468B2 (en) * | 2005-04-07 | 2011-04-05 | Centre National De La Recherche Scientifique (C.N.R.S.) | Compounds useful as modulators of the proteasome activity |
| US20080293639A1 (en) * | 2005-04-29 | 2008-11-27 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| EP1930017B1 (en) * | 2005-09-29 | 2012-05-23 | Maruha Nichiro Seafoods, Inc. | Composition effective for prevention and treatment of adult disease |
| JP2007217358A (ja) * | 2006-02-17 | 2007-08-30 | Nippon Meat Packers Inc | 抗酸化性ペプチド |
| WO2007117444A2 (en) * | 2006-03-31 | 2007-10-18 | Yinghe Hu | Protein detection by aptamers |
| US20090312396A1 (en) | 2006-07-10 | 2009-12-17 | Astrazeneca Ab | Methods for cancer treatment using tak1 inhibitors |
| WO2008021088A2 (en) * | 2006-08-08 | 2008-02-21 | The Regents Of The University Of Californina | Salicylanilides enhance oral delivery of therapeutic peptides |
| CN101153053B (zh) * | 2006-09-28 | 2012-02-01 | 中国医学科学院药物研究所 | 骨生肽、其制备方法和其药物组合物与用途 |
| EP1964560A1 (en) | 2007-02-28 | 2008-09-03 | Helmholtz-Zentrum für Infektionsforschung GmbH | Use of inhibitors of the degradation of p27 for the treatment of cancer |
| JP2011511076A (ja) | 2008-02-08 | 2011-04-07 | エイルロン セラピューティクス，インコーポレイテッド | 治療用ペプチド模倣大環状分子 |
| GB0918579D0 (en) | 2009-10-22 | 2009-12-09 | Imp Innovations Ltd | Gadd45beta targeting agents |
| EP2390662A1 (en) | 2010-05-27 | 2011-11-30 | Erasmus University Medical Center Rotterdam | Molecular classification of multiple myeloma |
-
2009
- 2009-10-22 GB GBGB0918579.4A patent/GB0918579D0/en not_active Ceased
-
2010
- 2010-10-22 MX MX2012004755A patent/MX357801B/es active IP Right Grant
- 2010-10-22 US US13/502,781 patent/US8993717B2/en active Active
- 2010-10-22 AU AU2010309594A patent/AU2010309594B2/en active Active
- 2010-10-22 RU RU2016102083A patent/RU2016102083A/ru not_active Application Discontinuation
- 2010-10-22 CA CA3034860A patent/CA3034860A1/en not_active Abandoned
- 2010-10-22 EP EP16185463.3A patent/EP3178836B1/en active Active
- 2010-10-22 CN CN201080058254.9A patent/CN102741269B/zh active Active
- 2010-10-22 JP JP2012534766A patent/JP5961113B2/ja active Active
- 2010-10-22 IN IN3310DEN2012 patent/IN2012DN03310A/en unknown
- 2010-10-22 EP EP10781977A patent/EP2491051A2/en not_active Withdrawn
- 2010-10-22 KR KR1020127013065A patent/KR20120099440A/ko not_active Ceased
- 2010-10-22 BR BR112012011332-1A patent/BR112012011332B1/pt active IP Right Grant
- 2010-10-22 CA CA2778236A patent/CA2778236A1/en not_active Abandoned
- 2010-10-22 RU RU2012120905/04A patent/RU2577311C2/ru active
- 2010-10-22 WO PCT/GB2010/001970 patent/WO2011048390A2/en not_active Ceased
-
2012
- 2012-04-22 IL IL219325A patent/IL219325B/en not_active IP Right Cessation
-
2015
- 2015-02-10 US US14/618,613 patent/US9518083B2/en active Active
-
2016
- 2016-03-25 JP JP2016060994A patent/JP2016166211A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN102741269A (zh) | 2012-10-17 |
| US20120277164A1 (en) | 2012-11-01 |
| CA3034860A1 (en) | 2011-04-28 |
| US20150368294A1 (en) | 2015-12-24 |
| JP2016166211A (ja) | 2016-09-15 |
| EP3178836B1 (en) | 2019-12-25 |
| AU2010309594A1 (en) | 2012-05-17 |
| KR20120099440A (ko) | 2012-09-10 |
| EP3178836A1 (en) | 2017-06-14 |
| BR112012011332A2 (pt) | 2016-11-22 |
| JP2013508346A (ja) | 2013-03-07 |
| WO2011048390A2 (en) | 2011-04-28 |
| BR112012011332B1 (pt) | 2022-07-05 |
| EP2491051A2 (en) | 2012-08-29 |
| JP5961113B2 (ja) | 2016-08-02 |
| IN2012DN03310A (OSRAM) | 2015-10-23 |
| RU2577311C2 (ru) | 2016-03-20 |
| RU2012120905A (ru) | 2013-11-27 |
| MX2012004755A (es) | 2012-11-22 |
| WO2011048390A3 (en) | 2011-11-03 |
| MX357801B (es) | 2018-07-25 |
| CA2778236A1 (en) | 2011-04-28 |
| AU2010309594B2 (en) | 2016-01-07 |
| IL219325A0 (en) | 2012-06-28 |
| US8993717B2 (en) | 2015-03-31 |
| CN102741269B (zh) | 2017-08-29 |
| GB0918579D0 (en) | 2009-12-09 |
| IL219325B (en) | 2019-02-28 |
| US9518083B2 (en) | 2016-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016102083A (ru) | Соединения, направленные на Gadd45β, и их включающая фармацевтическая композиция | |
| JP2013508346A5 (OSRAM) | ||
| EP3274360B1 (en) | Solution phase method for preparing etelcalcetide | |
| AU5433096A (en) | Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability | |
| RU2011122647A (ru) | Cxcr4-рецепторные соединения | |
| JP2000256397A (ja) | 新規な環状テトラペプチド誘導体とその医薬用途 | |
| JP2002514611A5 (OSRAM) | ||
| Moustafa et al. | Synthesis of novel cyclopeptide candidates: I-cyclo-[Nα-isophthaloyl-bis-(Glycine-amino acid)-L-lysine] derivatives with expected anticancer activity | |
| JP2009108078A5 (OSRAM) | ||
| WO2003059933A2 (en) | Conformationally constrained c-backbone cyclic peptides | |
| MX2010012042A (es) | Peptidos, peptidomimeticos y derivados de los mismos, su fabricacion asi como su uso para preparar una composicion farmaceutica terapeutica y/o preventivamente activa. | |
| US6855692B2 (en) | Histogranin peptides and their analgesic use | |
| CN101270153B (zh) | 一种环五肽及其合成方法 | |
| JP2015533369A5 (OSRAM) | ||
| JPS5973574A (ja) | 環状ジペプチド類 | |
| WO2008003067A3 (en) | Methods and compositions for improved uptake of biological molecules | |
| JP5433586B2 (ja) | ペプチド修飾の方法 | |
| Chang et al. | Stereoselective syntheses of tri-and tetrapeptide analogues by dynamic resolution of α-halo amides in nucleophilic substitution | |
| Webster et al. | Design and preparation of serine–threonine protein phosphatase inhibitors based upon the nodularin and microcystin toxin structures. Part 3 | |
| CA3029584A1 (en) | Process for preparation of icatibant acetate | |
| JP2006504786A5 (OSRAM) | ||
| PT95112B (pt) | Processo para a preparacao de derivados de peptido farmacologicamente activos | |
| Demin et al. | Synthesis of glutaryl-containing derivatives of GRGD and KRGD peptides | |
| Byk et al. | Synthesis and conformational analysis of peptide inhibitors of farnesyltransferase | |
| CN101203527A (zh) | 主链环化的促黑皮质素激素（αMSH）类似物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20190123 |